NeuroPace (NeuroPace) EBIT per Share : $-0.85 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NeuroPace EBIT per Share?

NeuroPace's EBIT per Share for the three months ended in Mar. 2024 was $-0.24. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.85.

During the past 3 years, the average EBIT per Share Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for NeuroPace's EBIT per Share or its related term are showing as below:

NPCE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 3.6 Med: 4.7 Max: 5.8
Current: 3.6

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of NeuroPace was 5.80% per year. The lowest was 3.60% per year. And the median was 4.70% per year.

NPCE's 3-Year EBIT Growth Rate is ranked worse than
53.65% of 727 companies
in the Medical Devices & Instruments industry
Industry Median: 5.8 vs NPCE: 3.60

NeuroPace's EBIT for the three months ended in Mar. 2024 was $-6.67 Mil.

NeuroPace EBIT per Share Historical Data

The historical data trend for NeuroPace's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroPace EBIT per Share Chart

NeuroPace Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-1.85

-1.15

-1.73

-1.61

-0.95

NeuroPace Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-0.34	-0.28	-0.20	-0.15	-0.24

NeuroPace EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

NeuroPace's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-24.439	/	25.852
=	-0.95

NeuroPace's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.667	/	28.285
=	-0.24

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.85

NeuroPace (NAS:NPCE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

NeuroPace EBIT per Share Related Terms

Thank you for viewing the detailed overview of NeuroPace's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroPace (NeuroPace) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

455 N. Bernardo Avenue, Mountain View, CA, USA, 94043

Website

https://www.neuropace.com

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Executives

Martha Morrell	officer: Chief Medical officer	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd.	10 percent owner	CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker	director, officer: Chief Executive Officer	ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger	director	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p.	10 percent owner	2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley	officer: General Counsel and Secretary	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade	director	6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield	director	C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer	director	9701 JERONIMO, IRVINE CA 92618
Evan Norton	director	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob	director	2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan	director	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet	director, officer: Chief Executive Officer	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043